Q1-2: Mogamulizumab

Question 1: Was the recipient treated with Mogamulizumab, alone or in combination, within one year PRIOR to allogeneic transplant?

Indicate if the recipient was treated with Mogamulizumab, alone or in combination, within one year PRIOR to allogeneic transplant. This question is intended to determine study eligibility.

Question 2: Was Mogamulizumab administered in the last line of therapy prior to transplant?

Indicate if Mogamulizumab was administered in the last line of therapy prior to transplant. This question is intended to determine cohort eligibility in the study.

Section Updates:

Question Number	Date of Change	Add/Remove/Modify	Description	Reasoning (If applicable)
.	.	.	.	.

Copyright © 2004-2025 The Medical College of Wisconsin, Inc. and NMDP. All Rights Reserved.
CIBMTR® (Center for International Blood and Marrow Transplant Research) is a research collaboration between the Medical College of Wisconsin and NMDP.